Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Version 2. F1000Res. 2013 May 31 [revised 2013 Oct 10];2:134. doi: 10.12688/f1000research.2-134.v2. eCollection 2013.

FAM129B is a novel regulator of Wnt/β-catenin signal transduction in melanoma cells.

Author information

  • 1The Howard Hughes Medical Institute, Seattle WA, 98195, USA ; Department of Pharmacology, University of Washington School of Medicine, Seattle WA, 98195, USA.
  • 2The Howard Hughes Medical Institute, Seattle WA, 98195, USA ; Department of Cell Biology and Physiology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill NC, 27599-7295, USA.
  • 3Rosetta Inpharmatics, LLC, Merck & Co Inc., Seattle WA, 98109, USA ; Merck & Co., Inc., West Point PA, 19486, USA.
  • 4Department of Automated Biotechnology, Merck, North Wales PA, 19454, USA ; NCATS/NIH, Rockville MD, 20850, USA.
  • 5Rosetta Inpharmatics, LLC, Merck & Co Inc., Seattle WA, 98109, USA ; Hudson Alpha Institute for Biotechnology, Huntsville AL, 35806, USA.
  • 6Department of Screening and Protein Sciences, Merck Research Laboratories, North Wales PA, 19454, USA.
  • 7Rosetta Inpharmatics, LLC, Merck & Co Inc., Seattle WA, 98109, USA ; Bristol-Myers Squibb Company, Applied Genomics, Princeton NJ, 08543, USA.
  • 8Rosetta Inpharmatics, LLC, Merck & Co Inc., Seattle WA, 98109, USA ; Seattle Genetics, Bothell WA, 98021, USA.
  • 9The Howard Hughes Medical Institute, Seattle WA, 98195, USA ; Department of Pharmacology, University of Washington School of Medicine, Seattle WA, 98195, USA ; The Institute for Stem Cell and Regenerative Medicine, Seattle WA, 98109, USA.
  • 10Division of Dermatology, Department of Medicine, University of Washington, Seattle WA, 98195, USA ; The Institute for Stem Cell and Regenerative Medicine, Seattle WA, 98109, USA.

Abstract

The inability of targeted BRAF inhibitors to produce long-lasting improvement in the clinical outcome of melanoma highlights a need to identify additional approaches to inhibit melanoma growth. Recent studies have shown that activation of the Wnt/β-catenin pathway decreases tumor growth and cooperates with ERK/MAPK pathway inhibitors to promote apoptosis in melanoma. Therefore, the identification of Wnt/β-catenin regulators may advance the development of new approaches to treat this disease. In order to move towards this goal we performed a large scale small-interfering RNA (siRNA) screen for regulators of β-catenin activated reporter activity in human HT1080 fibrosarcoma cells. Integrating large scale siRNA screen data with phosphoproteomic data and bioinformatics enrichment identified a protein, FAM129B, as a potential regulator of Wnt/β-catenin signaling.  Functionally, we demonstrated that siRNA-mediated knockdown of FAM129B in A375 and A2058 melanoma cell lines inhibits WNT3A-mediated activation of a β-catenin-responsive luciferase reporter and inhibits expression of the endogenous Wnt/β-catenin target gene, AXIN2. We also demonstrate that FAM129B knockdown inhibits apoptosis in melanoma cells treated with WNT3A. These experiments support a role for FAM129B in linking Wnt/β-catenin signaling to apoptosis in melanoma.

PMID:
24358901
[PubMed]
PMCID:
PMC3829391
Other versionsFree PMC Article

Images from this publication.See all images (5)Free text

Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for F1000 Research Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk